Global Healthy Living Foundation 50-State Network advocate Lisa Tent delivers Osteoporosis patient perspective to ICER, the Institute for Clinical and Economic Review.

Global Healthy Living Foundation President and Co-Founder, Seth Ginsberg, issued a powerful statement to Iowa Governor Terry Branstad urging him to support House Bill 233.

HB 233 takes positive steps toward updating Montana law to cover biologics and biosimilars in a way that protects patients. Unlike traditional chemical drugs, biologics are unique, complex structures made from living cells that are not easily replicated. A small change or difference in the biosimilar or biologic manufacturing process has the potential to adversely impact the patient. […]

Director of State and National Advocacy, Stephen Marmaras, commented on off label uses of medications on November 9th, 2016. He acknowledges the promise to patients off label usage offers, as well as the disparity of education between large medical centers and more isolated rural providers. Marmaras proposes further distribution of peer reviewed articles for education, […]

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

HB 505 takes positive steps toward updating Ohio law to cover biologics and biosimilars in a
way that protects patients. As you know, unlike traditional chemical drugs, biologics are unique,
complex structures made from living cells that are not easily replicated. A small change or
difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

HB 254 HD 2 takes positive steps toward updating Hawaii law to cover biologics and biosimilars
in a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in
a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

SB 313 takes positive steps toward updating Connecticut law to cover biologics and biosimilars
in a way that protects patients.